secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001437749-26-004739
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q4 rev $264K, GAAP net loss $17.4M; FDA clears pivotal AF study
--------------------------------------------------------------------------------

- Q4 2025 revenue $264K (vs $86K Q3), full-year revenue $350K. GAAP net loss Q4 $17.4M, full year $72.8M (vs $53.6M prior year).
- Cash $80.7M at Dec 31, 2025 (down from $118.0M at Dec 31, 2024); Q4 cash used in ops $14.8M.
- FDA approved pivotal IDE study for nPulse Cardiac Catheter System (paroxysmal AF); first patient expected in months, last patient Q4 2026.
- Feasibility study: 100% procedural success at 6 months, 96% at 1 year for AF ablation.
- Non-GAAP net loss Q4 $12.2M vs $10.4M prior year; full year $50.8M vs $36.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926004739/0001437749-26-004739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926004739/plse20251122_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-004739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer